Moderna Shares Surge Following Positive Phase 3 Cancer Vaccine Trial Results
Moderna's personalized mRNA cancer therapy, developed with Merck, met primary endpoints in a Phase 3 melanoma study.
Quick Look
- Moderna shares surged 131% after its mRNA-based personalized cancer vaccine, developed with Merck, achieved positive Phase 3 results for melanoma patients.
- The therapy, used alongside Keytruda, met recurrence-free and distant-metastasis-free survival goals.
AI-generated summary
Why It Matters
The INTerpath-001 trial evaluates the combination of intismeran autogene and Keytruda in patients with surgically removed stage IIB–IV melanoma.
Moderna's personalized mRNA cancer shot cleared its first Phase 3 readout, and the market reacted like it had won more than a trial.
Shares of Moderna, which trades as MRNA, surged about 131% on Wednesday, more than doubling to near $148 after touching $163 intraday, a record one-day jump. Merck (MRK), the larger partner that sells Keytruda, also spiked on the news.
The companies said the Phase 3 INTerpath-001 trial of intismeran autogene plus Keytruda met its recurrence-free and distant-metastasis-free survival goals in patients whose stage IIB–IV melanoma had been surgically removed.
It's the first positive Phase 3 result for a personalized neoantigen therapy, and the first for an mRNA-based cancer treatment.
What the therapy actually does
Intismeran autogene (also called V940 or mRNA-4157) isn't a mass-produced vial. Doctors sequence a patient's tumor, map its unique mutations, and the mRNA teaches the body to manufacture neoantigens—protein fragments the immune system learns to spot and attack.
Keytruda, an anti-PD-1 drug, lifts the brakes on immune cells. Together they're meant to scrub out any cancer surgery left behind.
The combo developed by Moderna and Merck beat Keytruda alone, the current standard of care, on both endpoints. That's the first time a personalized neoantigen therapy has shown a clinically meaningful edge over the blockbuster immunotherapy in the adjuvant setting (treatment after surgery to prevent return). For Moderna, which has leaned on a collapsed COVID franchise and carried one of the heaviest short bets among large caps, the readout lands at a make-or-break hour.
It also lit a fuse. When a heavily shorted stock rockets, borrowers scramble to buy back and stop the bleeding—the same short-squeeze mechanics that rattled markets during the 2021 GameStop frenzy. Crypto-linked equities recently handed short sellers $2.6 billion in losses as rallies reversed, and Moderna's move was far bigger.
"With each shorted share now down almost $100, that is exactly the kind of pressure that can trigger a squeeze," ORTEX co-founder Peter Hillerberg said in a statement.
The trial will continue to evaluate overall survival and other secondary endpoints not yet reported.
What to Watch
AI outlook — possibilities, not facts
The trial will continue to evaluate overall survival and secondary endpoints.
Very likely · Within months
Open Questions
- What are the long-term overall survival statistics?
- When will the therapy be submitted for regulatory approval?
